Dapagliflozin (DAPA)

DRUG19 trials

Sponsors

Woman's, The First Affiliated Hospital of Soochow University, Beneficência Portuguesa de São Paulo, Lauro Fabián Amador Medina, Al-Azhar University

Conditions

Acute Decompensated Heart Failure (ADHF)AlbuminuriaAnemiaAnemia, Kidney Disease, ChronicAortic StenosisArrhythmias, CardiacAtrial Fibrillation (AF)CKD

Early Phase 1

Effects of Sodium-Glucose Co-transporter 2 Inhibitors on Inflammation

CompletedNCT06812429

Washington University School of MedicineInflammation

Start: 2024-05-08End: 2025-04-05Updated: 2026-01-07

Phase 1

Dapagliflozin on Outcomes of Rhythm Control Strategy (Pharmacological ± Interventional) in Patient with Atrial Fibrillation

Not yet recruitingNCT06759909

Assiut UniversityAtrial Fibrillation (AF), Dapagliflozin (Forxiga)

Start: 2025-01-03End: 2028-12-22Target: 100Updated: 2025-01-06

Dapagliflozin in Nonalcoholic Fatty Liver Disease (NAFLD) and Type 2 Diabetes Mellitus Patients (T2DM).

Active, not recruitingNCT07020377

Amira Bisher,PhDDiabetes Mellitus, Non Alcholic Fatty Liver Disease

Start: 2024-01-15End: 2025-12-30Target: 60Updated: 2025-06-13

Phase 2

Dapagliflozin in Allo-HCT for aGVHD

RecruitingNCT06626737

The First Affiliated Hospital of Soochow UniversityGraft-versus-host Disease (GVHD)

Start: 2025-04-26End: 2026-12-31Target: 72Updated: 2025-06-05

Dapagliflozin as Prophylaxis for Glucocorticoid-Induced Hyperglycemia

Active, not recruitingNCT06748105

Lauro Fabián Amador MedinaDapagliflozin (Forxiga), Glucocorticoid, Hyperglycaemia

Start: 2024-12-01End: 2025-12-01Target: 38Updated: 2024-12-27

Impact of Dapagliflozin in Anemic Chronic Kidney Disease Patients

RecruitingNCT06897605

Mansoura UniversityAnemia, Kidney Disease, Chronic, Chronic Kidney Disease(CKD)

Start: 2025-04-01End: 2025-10-31Target: 80Updated: 2025-04-02

To Establish Whether Dapagliflozin and Spironolactone in Patients With Severe Aortic Stenosis Undergoing Aortic Valve Replacement, Result in Better Left Ventricular Mass Regression, Myocardial Health and Patient Reported Outcomes

Not yet recruitingNCT07539259

University College, LondonAortic Stenosis

Start: 2026-12-01End: 2030-02-28Target: 445Updated: 2026-05-18

Phase 3

EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)

CompletedNCT02635386

Woman'sObesity, Polycystic Ovary Syndrome

Start: 2016-03-22End: 2020-10-09Updated: 2021-01-29

Cardio Protective Effect of SGL2I in Hemodialysis Patients and Its Impact on Patient Quality of Life

Active, not recruitingNCT06759077

Al-Azhar UniversityKidney Diseases

Start: 2024-12-28End: 2025-12-28Updated: 2025-01-08

Effects Dapagliflozin on Inflammatory Markers Erythropoiesis and Iron Metabolism in Patients with Type 2 Diabetes and CKD

Not yet recruitingNCT06820567

Assiut UniversityChronic Kidney Diseases, Diabetes Type 2

Start: 2025-03-01End: 2027-05-01Target: 210Updated: 2025-02-11

Dapagliflozin for Long COVID Syndrome

Not yet recruitingNCT06907251

Ottawa Heart Institute Research CorporationCOVID - 19, Long COVID Syndrome, SARS CoV-2

Start: 2026-04-01End: 2029-06-30Target: 192Updated: 2026-05-01

A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus

RecruitingNCT07082114

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Type 2 Diabetes

Start: 2025-07-14End: 2027-05-17Target: 800Updated: 2025-07-24

Phase 4

Effect of Dapagliflozin on Electrocardiographic Parameters in Type 2 Diabetes Patients: DAPA - ECG Study

CompletedNCT06721442

Beneficência Portuguesa de São PauloArrhythmias, Cardiac, Diabetes Mellitus

Start: 2023-01-10End: 2024-07-10Updated: 2024-12-06

Can the Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Prevent the Increase in Plasma Ketone Concentration?

Not yet recruitingNCT06922656

Dasman Diabetes InstituteType 1 Diabetes

Start: 2025-09-15End: 2027-01-15Target: 60Updated: 2025-08-29

Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study

Enrolling by invitationNCT06954090

Steno Diabetes Center CopenhagenAlbuminuria, Type 2 DM, Type 2 DM /Diabetic Nephropathy

Start: 2025-11-20End: 2027-05-31Target: 50Updated: 2025-12-22

The Effect of Dapagliflozin on Patients With Cardiomyopathy

RecruitingNCT07076615

May Mohamed AbdallaAcute Decompensated Heart Failure (ADHF)

Start: 2025-08-31End: 2026-05-31Target: 100Updated: 2025-08-22

The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity

CompletedNCT07120828

Erbil Polytechnic UniversityObese Diabetics, Obese Patients (BMI ≥ 30 kg/m²), Type 2 Diabetes

Start: 2025-07-15End: 2026-03-15Updated: 2026-03-17

Unknown Phase

The Effect of Combination of Dapagliflozin and Sildenafil in Treatment of Heart Failure Patients With Secondary Pulmonary Hypertension

CompletedNCT06778330

Fayoum UniversityHeart Failure NYHA Class II

Start: 2025-01-20End: 2025-08-01Updated: 2025-09-03

Anemia-Related Outcomes in Patients With CKD Treated With Dapagliflozin

Active, not recruitingNCT06813222

Damanhour UniversityAnemia, CKD

Start: 2021-04-01End: 2025-03-01Target: 100Updated: 2025-02-06

Related Papers

Effect of dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, on ventricular repolarization electrocardiographic parameters in type 2 diabetes patients: DAPA - ECG study

Frontiers in Clinical Diabetes and Healthcare2025-03-311 citations